Paris

• Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting
  2023-504923-20-00 5 2024-04-04 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
• A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe … Recruiting
  2023-503412-33-00 5 2024-03-29 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
• A study of STX-721/PFL-721 in participants with non-small cell lung cancer with certain mutations Recruiting
  2023-506759-51-00 7 2024-03-29 Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• DUMELEP trial - Durvalumab (MEDI4736)/Tremelimumab in neoadjuvant and adjuvant setting in patients with HCC treated by percutaneous ablation … Recruiting
  2024-515768-30-01 4 2024-03-28 Hepatocellular carcinoma
• Multicenter randomized Phase III trial evaluating contact X-ray brachytherapy for rectal preservation in intermediate substage rectal adenoc … Recruiting
  2023-506885-30-00 5 2024-03-26 Adult patients with intermediate low or mid rectal adenocarcinoma to b
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• PLGG – MEKTRIC (Pediatric Low Grade Glioma – MEKinhibitor TRIal vs Chemotherapy) Recruiting
  2023-508531-30-00 4 2024-03-25 grade 1 glioma/mixed glio-neuronal tumors or pleomorphic xanthoastrocy
• Efficacy of 7 days versus 14 days of antibiotic therapy for acute pyelonephritis in kidney transplant recipients Recruiting
  2024-513328-40-00 6 2024-03-25 Pyelonephritis
• FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab … Recruiting
  2022-501554-11-00 4 2024-03-21 Patients with previously untreated Richter’s syndrome (RS), defined as
• A study to assess the safety and efficacy of IPN10200 in adult participants with moderate to severe upper facial lines Recruiting
  2024-512782-14-00 7 2024-03-20 Treatment of Moderate to Severe Upper Facial Lines
• A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) … Recruiting
  2023-504323-25-01 5 2024-03-19 breast cancer
• A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PASADENA) Recruiting
  2023-504472-24-00 4 2024-03-19 Early Idiopathic Parkinson’s disease (PD)
• ​​Lomustine with or without a second round of brain radiation for the reappearance of glioblastoma Recruiting
  2023-505267-36-00 5 2024-03-15 Glioblastoma
• Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Crohn’s Disease Recruiting
  2023-504735-41-00 5 2024-03-05 Moderately to Severely Active Crohn's Disease
• OPtimisation of antiviral Therapy in Immunocompromised COVID-19 patients: a randomized factorial controlled strategy trial: the OPTICOV Stud … Recruiting
  2022-501408-81-01 4 2024-03-04 Covid-19
• RECOVERY Recruiting
  2023-507441-29-00 5 2024-02-29 Pneumonia
• An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi … Recruiting
  2022-501453-36-00 5 2024-02-23 Breast cancer
• Treatment for breast cancer patients with meninges invaded by tumor cells Recruiting
  2022-502351-60-00 4 2024-02-22 Patients having a HER2-amplified metastatic breast cancer with evoluti
• A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adul … Recruiting
  2023-504863-17-00 5 2024-02-21 1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic Cutaneous Lupus
• Weaning protocol for high-flow nasal oxygen therapy in the ICU - Multicenter randomized controlled trial. HiFloWEAN Recruiting
  2023-504366-36-00 5 2024-02-17 de novo acute respiratory failure
• An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced … Recruiting
  2023-503865-48-00 4 2024-02-16 Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• An Open-label Study of XEN1101 in Epilepsy Recruiting
  2022-502282-24-00 5 2024-02-14 Primary generalized tonic-clonic seizures
• Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors Recruiting
  2023-506604-18-00 1 2024-02-14 Triple negative breast cancer
• Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU) Recruiting
  2024-516402-32-00 5 2024-02-13 Adult patients with aHUS associated with HE and severe kidney involvem

Showing 985–1,008 of 2,286 trials